3T-thanks for sharing. That’s an enlightening article and the emphasis is clearly on a precision medicine type treatment and indirectly on Anavex. Most interesting is that the company comparative financial analysis gives Anavex a CURRENT NPV of 750M. For those non finance types that correlates to a 15 share price. Very clear something amiss with the current market cap (and selling price).
Very nice article 1. A2-73 still is called as P2 R&D drug - not a P3 drug - that shows that it is much farther away than approval 2. Good that M was quoted in the article few times - will give some visibility
Anavex featured in this story from the healthcare news team at S&P Global Market Intelligence, including quotes throughout from an interview they conducted with Dr. Missling: Failures in Alzheimer's research spur new approaches to drug development
Thanks TTT for the NPV S&P post and others for the analysis. There could be some euphoric moments in our future. More with 2-73 than without. So much good coming our way and so much owed to those that laid down their young lives for USA.